L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-?-glutamyl-L-arginyl-L-?-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L-lysyl-L-alanyl-L-threonyl-L-?-glutamyl-L-arginyl-L-leucyl-L-alanyl-5-carboxy-L-norvalyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-seryl-L-phenylalanyl-N-methylglycyl-L-alanyl-N-methyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-?-glutamyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-4-hydroxy-, (3?8)-lactam, (4R)-
Type 2 Diabetes
Zealand Pharmaprotein_peptidePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
141 Active assets in the Type 2 Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide RenJi Hospital | Phase 4 | BBB |
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Cotadutide AstraZeneca | Phase 2 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-?-glutamyl-L-arginyl-L-?-aspartylglycyl-L-threonyl-L-alanyl-L-threonyl-L-lysyl-L-alanyl-L-threonyl-L-?-glutamyl-L-arginyl-L-leucyl-L-alanyl-5-carboxy-L-norvalyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-seryl-L-seryl-L-phenylalanyl-N-methylglycyl-L-alanyl-N-methyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-?-glutamyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-4-hydroxy-, (3?8)-lactam, (4R)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →